Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, et al.
Scientific Reports|February 25, 2017
Thyroid nodule sizes influence the diagnostic performance of TIRADS and ultrasound patterns of 2015 ATA guidelines: a multicenter retrospective studyTing Xu, Jing-Yu Gu, Xin-Hua Ye, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
Molecular Cancer Therapeutics|August 26, 2017
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine TumorsAllison S Harney, George S Karagiannis, Jeanine Pignatelli, et al.
Molecular Cancer Therapeutics|August 20, 2015
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Bryan D Smith, Michael D Kaufman, Cynthia B Leary, et al.
Cancer Cell|April 13, 2011
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036Wayne W Chan, Scott C Wise, Michael D Kaufman, et al.
Cancer Cell|September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersSheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Cancer Cell|May 16, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA VariantsBryan D Smith, Michael D Kaufman, Wei-Ping Lu, et al.
Pageof 4